For example, the following top 100 MDS genes can be mentioned that are not yet covered by approved or experimental cancer or antineoplastic drugs [according to DrugBank (Law et al., 2014), DGIdb (Cotto et al., 2018), FDA6, HMDB (Wishart et al., 2018), Tocris7, GeneCards (Safran et al., 2010) databases]: GRB2, SOS1,SOS2, SHC1, GNB1, CREB1, GNG2, GNAQ, GNB5, GNAI2. This evidence concerns the gene CREB1 and myelodysplastic syndrome.